MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
3.190
+0.170 (5.63%)
At close: Oct 15, 2026, 4:00 PM EDT
3.200
+0.010 (0.31%)
After-hours: Oct 15, 2026, 7:30 PM EDT
MannKind Revenue
MannKind had revenue of $109.37M in the quarter ending June 30, 2026, with 42.92% growth. This brings the company's revenue in the last twelve months to $393.63M, up 30.46% year-over-year. In the year 2025, MannKind had annual revenue of $348.97M with 22.23% growth. That makes MannKind the 12,635th largest company in the world by revenue and 2,451st in the United States.
Revenue (ttm)
$393.63M
Revenue Growth
+30.46%
P/S Ratio
2.61
Revenue / Employee
$664,914
Employees
592
Market Cap
1.03B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 348.97M | 63.46M | 22.23% |
| Dec 31, 2024 | 285.50M | 86.54M | 43.50% |
| Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
| Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
| Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
| Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
| Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
| Dec 31, 2018 | 27.86M | 16.11M | 137.20% |
| Dec 31, 2017 | 11.75M | -163.01M | -93.28% |
| Dec 31, 2016 | 174.76M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 397.50M |
| Immatics | 47.65M |
| Janux Therapeutics | 24.00M |
| Aktis Oncology | 10.06M |
| SL Science Holding | 3.27M |
MNKD News
- 1 day ago - MannKind to Participate in the Chardan Healthcare Conference - GlobeNewsWire
- 15 days ago - Liquidia ruling has positive read-through for MannKind Tyvaso DPI, says Truist - TheFly
- 4 weeks ago - MannKind Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - MannKind management to meet with Cantor - TheFly
- 5 weeks ago - MannKind and Rose Pharma sign licensing and collaboration agreement - TheFly
- 5 weeks ago - MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - GlobeNewsWire
- 6 weeks ago - MannKind to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - MannKind price target lowered to $13 from $14 at Wells Fargo - TheFly